Consent Matters

Consent Matters

Marketing consent challenges for European-based pharmaceutical companies

Data is essential to all marketers - we use it to ensure that we are reaching the right audiences with our messaging, and to better understand what Healthcare Professionals (HCPs) want/need so that we can communicate with them more effectively. At the same time, increasing regulations, technology advancements and growing privacy concerns are creating a significant challenge to European-based pharmaceutical companies digital engagement strategy.

Post COVID-19, the pharmaceutical industry understands the value of digital engagements, and having consent plays a huge part in its ability to connect and communicate with HCPs in a more personalised and compliant manner.

Today, I want to share with you some key considerations and challenges when it comes to obtaining marketing consent from HCPs.

Compliant with GDPR
One of the biggest challenges for pharmaceutical companies is ensuring that their marketing consent processes are compliant with the General Data Protection Regulation (GDPR) and other privacy laws. Companies must obtain explicit consent from HCPs for the use of their data for marketing purposes, and this consent must be obtained in a transparent and straightforward manner.

Balancing Privacy and Marketing
Another challenge for pharmaceutical companies is balancing the need for privacy protection with the desire to reach HCPs with marketing messages. Companies need to find a way to obtain consent from HCPs while also respecting their privacy rights and avoiding intrusive marketing tactics.

Building and maintaining trust is critical for obtaining marketing consent, but it can be challenging for pharmaceutical companies that are subject to strict regulations and scrutiny. Companies need to be transparent about their data practices and ensure that they are using data responsibly.

Opt-out Rates
Despite efforts to obtain consent, some HCPs may still opt-out of marketing communications. Pharmaceutical companies must be prepared for this and find ways to continue reaching HCPs through alternative channels.

Personalising marketing efforts can be challenging for pharmaceutical companies, as they need to ensure that they have the right data and insights to create targeted, relevant communications. Companies must strike a balance between personalisation and privacy and ensure that they are using data in a responsible manner.

Building the digital bridge
It’s clear that by being transparent about your data practices, balancing privacy, building trust, and finding creative solutions to these challenges, pharmaceuticals can increase the chances of obtaining the consent needed to reach HCPs with the right marketing messages.

This is an exciting time for pharmaceutical digital marketers. Regardless of where you are in your consent or outreach journey, the experienced Health Team at Loop Horizon can help you future-proof your adoption of a scalable consent framework for your 1:1 digital engagement in 2023.

Latest Articles

All Articles

Loop Horizon welcomes Misha Mansigani

She brings a wealth of extremely valuable client-side and vendor experience that will be very beneficial

March 2, 2023

How Pharma Services & Biotech Companies Can Create Value by Investing in UX

Can pharmaceutical companies embrace great UX design in their modern commercial digital and marketing operations...

February 24, 2023

2023 Omnichannel Trends to Look Out For in Pharma

Here are some of the top trends that are likely to shape the omnichannel strategies of pharmaceutical companies in 2023

February 17, 2023